Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Front Oncol. 2020 Aug 19:10:1448. doi: 10.3389/fonc.2020.01448. eCollection 2020.

Authors

Alexandra Lindsey Zune Djomkam^{1

2}, Charles Ochieng' Olwal^{1

2}, Theodore Beyeme Sala³, Lily Paemka^{1

2}

Affiliations

¹ West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.
² Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
³ Department of Urology, Laquintinie Hospital, Douala, Cameroon.

No abstract available

Keywords: ACE2; COVID-19; SARS-CoV-2; TMPRSS2; coronavirus; prostate cancer.

Publication types

Comment

Grants and funding

WT_/Wellcome Trust/United Kingdom